Saturday, June 13, 2026

Patent directory · USPTO A61K / A61P

Patents matching “ONC”

274 pharma patents match "ONC" in our USPTO index (A61K/A61P) — applicant, grant date, expiration, and drug links.

Matches 274
Index total 30,257
Page 4 / 12

Quick answer

This filtered view shows 274 pharmaceutical patents matching "ONC" in our USPTO PatentsView index (CPC A61K/A61P). Search matches patent number, title, applicant, and CPC classification codes.

Patent results

274 results for “ONC” · 30,257 patents in full index Clear search

  1. US 11020436

    Multipotent and immunocompatible stem cell concentrate

    REGENERA—MEDICINA VETERINÁRIA AVANÇADA LTDA. · Granted Jun 1, 2021 · Expires May 27, 2041

    granted
  2. US 11013767

    Materials and methods for engineering cells and uses thereof in immuno-oncology

    CRISPR THERAPEUTICS AG · Granted May 25, 2021 · Expires May 20, 2041

    granted
  3. US 10980793

    Methods of treating cancer with farnesyltransferase inhibitors

    Kura Oncology, Inc. · Granted Apr 20, 2021 · Expires Apr 15, 2041

    granted
  4. US 10973817

    Pharmaceutical compounds

    SENTINEL ONCOLOGY LIMITED · Granted Apr 13, 2021 · Expires Apr 8, 2041

    granted
  5. WO 2021052960

    COMPOSITION RADIOPHARMACEUTIQUE CONCENTRÉE, STABLE

    ADVANCED ACCELERATOR APPLICATIONS ITALY SRL [IT] · Granted Mar 25, 2021 · Expires Mar 20, 2041

    granted
  6. US 10953187

    Configurable oxygen concentrator and related method

    SEPARATION DESIGN GROUP LLC · Granted Mar 23, 2021 · Expires Mar 18, 2041

    granted
  7. US 10946080

    Compositions and methods for combination therapy with dengue virus and dendritic cells

    PrimeVax Immuno-Oncology · Granted Mar 16, 2021 · Expires Mar 11, 2041

    granted
  8. US 10881689

    Materials and methods for engineering cells and uses thereof in immuno-oncology

    CRISPR THERAPEUTICS AG · Granted Jan 5, 2021 · Expires Dec 31, 2040

    granted
  9. US 10857184

    Materials and methods for engineering cells and uses thereof in immuno-oncology

    CRISPR THERAPEUTICS AG · Granted Dec 8, 2020 · Expires Dec 3, 2040

    granted
  10. US 10842835

    Oncolytic vaccinia virus mutants and using same for cancer treatment

    ARIZONA BOARD OF REGENTS FOR AND ON BEHALF OF ARIZONA STATE UNIVERSITY · Granted Nov 24, 2020 · Expires Nov 19, 2040

    granted
  11. US 10842800

    Concomitant administration of glucocorticoid receptor modulators and CYP3A inhibitors

    Corcept Therapeutics Incorporated · Granted Nov 24, 2020 · Expires Nov 19, 2040

    granted
  12. US 2020353106

    Stable, concentrated radionuclide complex solutions

    ADVANCED ACCELERATOR APPLICATIONS ITALY SRL [IT] · Granted Nov 12, 2020 · Expires Nov 7, 2040

    granted
  13. US 10806730

    Methods of treating cancer with farnesyltransferase inhibitors

    Kura Oncology, Inc. · Granted Oct 20, 2020 · Expires Oct 15, 2040

    granted
  14. US 10765727

    Compositions and methods for producing dendritic cells

    PrimeVax Immuno-Oncology · Granted Sep 8, 2020 · Expires Sep 3, 2040

    granted
  15. US 10738123

    Anti-FLT-1 antibodies in treating bronchopulmonary dysplasia

    The Regents of the University of Colorado, a Body Corporate · Granted Aug 11, 2020 · Expires Aug 6, 2040

    granted
  16. US 10736919

    Materials and methods for engineering cells and uses thereof in immuno-oncology

    CRISPR THERAPEUTICS AG · Granted Aug 11, 2020 · Expires Aug 6, 2040

    granted
  17. US 10729725

    Materials and methods for engineering cells and uses thereof in immuno-oncology

    CRISPR THERAPEUTICS AG · Granted Aug 4, 2020 · Expires Jul 30, 2040

    granted
  18. US 10730882

    2-aminoquinazoline derivatives as P70S6 kinase inhibitors

    SENTINEL ONCOLOGY LIMITED · Granted Aug 4, 2020 · Expires Jul 30, 2040

    granted
  19. US 10716869

    Radiolabeled macrocyclic EGFR inhibitor

    Oncodesign SA · Granted Jul 21, 2020 · Expires Jul 16, 2040

    granted
  20. US 10675304

    Combination immunotherapies for treatment of cancer

    PrimeVax Immuno-Oncology · Granted Jun 9, 2020 · Expires Jun 4, 2040

    granted
  21. US 10676486

    Macrocyclic RIP2 kinase inhibitors

    Oncodesign SA · Granted Jun 9, 2020 · Expires Jun 4, 2040

    granted
  22. US 10647785

    High concentration chitosan-nucleic acid polyplex compositions

    ENGENE, INC. · Granted May 12, 2020 · Expires May 7, 2040

    granted
  23. US 10603351

    Engineered synergistic oncolytic viral symbiosis

    TURNSTONE LIMITED PARTNERSHIP · Granted Mar 31, 2020 · Expires Mar 26, 2040

    granted
  24. US 10596260

    Reoviruses having modified sequences

    ONCOLYTICS BIOTECH INC. · Granted Mar 24, 2020 · Expires Mar 19, 2040

    granted